European Primary Care Cardiovascular Society

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Jan. 2, 2024 - Jeff Healey, MD

GLP-1RA reduces risk of CV events associated with overweight and obesity

3' education - Jan. 2, 2024 - Michael Lincoff, MD

Three fascinating new strategies for lipid management

3' education - Dec. 14, 2023 - Karol Watson, MD, PhD

Novel insights on the importance of dietary sodium reduction

3' education - Dec. 14, 2023 - Deepak Gupta, MD

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD

Benefit with bempedoic acid in reducing total incidence of MACE

3' education - Oct. 9, 2023 - Stephen Nicholls, MD

CVD impacts all areas of the economy

3' education - Oct. 9, 2023 - Iris Harmsen, MD and Ramón Luengo-Fernandez, PhD

Ferric carboxymaltose as another tool in the toolkit for patients with HF and iron deficiency

3' education - Oct. 9, 2023 - Robert Mentz, MD

Unique randomized withdrawal heart failure trial with SGLT2i

3' education - Oct. 9, 2023 - Milton Packer, MD

Clinically meaningful benefits with GLP-1RA in patients with HFpEF and obesity

3' education - Oct. 9, 2023 - Mikhail Kosiborod, MD

Unexpected results after switching from VKA to DOAC in older frail patients with AF

3' education - Oct. 9, 2023 - Linda Joosten, MD

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - July 13, 2023 - Jozine ter Maaten, MD, PhD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - July 13, 2023 - Robert Mentz, MD

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - July 13, 2023 - Jasper Brugts, MD, PhD

Regional differences in prescription of PCSK9i therapy across Europe

10' education - July 12, 2023 - Maciej Banach, MD, PhD

The right therapy for the right patient

3' education - June 26, 2023 - Stephen Nicholls, MD

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - June 26, 2023 - Peter Libby, MD

How to manage patients with elevated Lp(a)

3' education - June 26, 2023 - Florian Kronenberg, MD, PhD

Relevance of adipose tissue in cardio-metabolic complications

3' education - June 26, 2023 - Antonio Vidal-Puig, MD

Fitting in bempedoic acid in the arsenal of lipid-lowering therapies

3' education - Mar. 30, 2023 - Prof. Kausik Ray, MD

Dual GIP/GLP-1RA reduces ambulatory blood pressure in adults with overweight or obesity

Literature - Feb. 13, 2024 - de Lemos JA, et al. - Hypertension. 2024

In a substudy of SURMOUNT-1, tirzepatide reduced ambulatory blood pressure in adults with a BMI ≥27 kg/m² compared with placebo.

Sitting at work associated with all-cause and cardiovascular mortality

Literature - Feb. 12, 2024 - Gao W, et al. - JAMA Netw Open. 2024

In a large prospective Taiwanese cohort study, prolonged occupational sitting was associated with higher risk of mortality compared with occupational nonsitting. The associated harm of prolonged occupational sitting was attenuated by alternating between sitting and nonsitting, as well as increasing physical activity.

Higher stress in adolescence and young adulthood associated with greater cardiometabolic risk

Literature - Feb. 7, 2024 - Guo F, et al. - J Am Heart Assoc. 2024

An 18-year prospective study suggested that higher perceived stress in adolescence and young adulthood and high stress levels over time may contribute to increased cardiometabolic risk in young adults.

Diagnosis and management of children and adolescents with familial hypercholesterolemia

Literature - Jan. 15, 2024 - European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration - - Lancet. 2023

In an international cross-sectional registry study, classic diagnostic features of familial hypercholesterolemia were uncommon in individuals aged <18 years, and the diagnosis therefore relied on LDL-c levels or genetic confirmation. Most participants were not on lipid-lowering therapy.

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Jan. 2, 2024 - Jeff Healey, MD
**AHA 2023** In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

AHA 2023 In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

GLP-1RA reduces risk of CV events associated with overweight and obesity

3' education - Jan. 2, 2024 - Michael Lincoff, MD
**AHA 2023** Michael Lincoff shares the results of the SELECT trial. “This trial is the first to show a weight-management therapy in a rigorous randomized trial to reduce the risk of CV events associated with overweight and obesity, and now positions overweight and obesity as a modifiable risk factor for CVD” said Lincoff.

AHA 2023 Michael Lincoff shares the results of the SELECT trial. “This trial is the first to show a weight-management therapy in a rigorous randomized trial to reduce the risk of CV events associated with overweight and obesity, and now positions overweight and obesity as a modifiable risk factor for CVD” said Lincoff.

Three fascinating new strategies for lipid management

3' education - Dec. 14, 2023 - Karol Watson, MD, PhD

AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab.

Novel insights on the importance of dietary sodium reduction

3' education - Dec. 14, 2023 - Deepak Gupta, MD
**AHA 2023** Deepak Gupta talks about the novel insights that the CARDIA-SSBP study provides on the effects of dietary sodium reduction on blood pressure.

AHA 2023 Deepak Gupta talks about the novel insights that the CARDIA-SSBP study provides on the effects of dietary sodium reduction on blood pressure.

Elderly people also benefit from lipid-lowering therapy for primary prevention

Literature - Nov. 29, 2023 - Andersson NW, et al. - J Am Coll Cardiol. 2023

In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.

GLP-1RA reduces CV outcomes in patients with overweight or obesity without diabetes

News - Nov. 28, 2023

AHA 2023 In the SELECT trial, subcutaneous semaglutide 2.4 mg once weekly reduced the risk of CV events in patients with preexisting CVD and overweight or obesity who do not have diabetes.

DOAC reduces stroke in patients with subclinical atrial fibrillation

News - Nov. 28, 2023

AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.

BP lowering reduces dementia in patients with hypertension

News - Nov. 28, 2023

AHA 2023 In the absence of curative therapies for dementia, it was investigated whether a BP-lowering intervention can reduce the risk of dementia in patients with hypertension in China.

Agenda